Patents Issued in July 4, 2019
-
Publication number: 20190202911Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.Type: ApplicationFiled: September 7, 2017Publication date: July 4, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
-
Publication number: 20190202912Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.Type: ApplicationFiled: September 21, 2017Publication date: July 4, 2019Inventors: Linda Liu, Benjamin Dallas Flies, Solomon Langermann
-
Publication number: 20190202913Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.Type: ApplicationFiled: March 21, 2019Publication date: July 4, 2019Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Publication number: 20190202914Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.Type: ApplicationFiled: December 19, 2018Publication date: July 4, 2019Inventors: Xin GAN, Yun HE, Yuqiang SHEN, Jiuqiao ZHAO, Yiping RONG
-
Publication number: 20190202915Abstract: The present invention provides a novel method of obtaining data for predicting the onset of an adverse event due to administration of at least one antibody drug selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, and an antigen-binding fragment thereof, or a novel method of predicting the onset of the adverse event. More specifically, the present invention provides a method of obtaining data for predicting the onset of an adverse event or a method of predicting the onset of the adverse event, comprising measuring a level of at least one marker selected from sCD163 and CXCL5 in a biological sample collected from a subject administered the antibody drug.Type: ApplicationFiled: June 30, 2017Publication date: July 4, 2019Applicant: TOHOKU UNIVERSITYInventor: Taku FUJIMURA
-
Publication number: 20190202916Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-L1 or PD-L2 by administering to the patient a nanoparticle composition and a PD-1 immunotherapy.Type: ApplicationFiled: August 31, 2017Publication date: July 4, 2019Inventors: Svetomir N. Markovic, Wendy K. Nevala
-
Publication number: 20190202917Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.Type: ApplicationFiled: June 20, 2017Publication date: July 4, 2019Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
-
Publication number: 20190202918Abstract: The instant disclosure provides chimeric polypeptides which modulate various cellular processes following a cleavage event induced upon binding of a specific binding member of the polypeptide with its binding partner. Methods of using chimeric polypeptides to modulate cellular functions, including e.g., induction of gene expression, are also provided. Nucleic acids encoding the subject chimeric polypeptides and associated expression cassettes and vectors as well as cells that contain such nucleic acids and/or expression cassettes and vectors are provided. Also provided, are methods of treating a subject using the described components and methods as well as kits for practicing the subject methods.Type: ApplicationFiled: August 22, 2017Publication date: July 4, 2019Inventors: Wendell A. Lim, Kole T. Roybal, Jasper Z. Williams
-
Publication number: 20190202919Abstract: Provided herein are methods of purifying anti-c-met antibodies, compositions, and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same.Type: ApplicationFiled: June 27, 2018Publication date: July 4, 2019Applicant: Genentech, Inc.Inventors: Marc WONG, Jerome J. BILL, JR., Arick M. BROWN, Glen S. GIESE, Judy Fay-Chen HSII, Amy LIM, Josefine PERSSON, Asha N. RADHAMOHAN, Maricel RODRIGUEZ
-
Publication number: 20190202920Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.Type: ApplicationFiled: July 19, 2017Publication date: July 4, 2019Applicant: F-STAR BETA LIMITEDInventors: Mihriban TUNA, Kin-Mei LEUNG, Haijun SUN, Melanie MEDCALF, Samine ISAAC
-
Publication number: 20190202921Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.Type: ApplicationFiled: January 9, 2019Publication date: July 4, 2019Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
-
Publication number: 20190202922Abstract: Isolated or recombinant Eph A5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vim methodologies is also provided.Type: ApplicationFiled: September 21, 2017Publication date: July 4, 2019Inventors: RENATA PASQUALINI, WADIH ARAP, FERNANDA IAMASSAKA STAQUICINI, FORTUNATO FERRARA, ANDREW R.M. BRADBURY
-
Publication number: 20190202923Abstract: Production of a chimeric antigen receptor (CAR) expressing cell having excellent target cytotoxicity. Provided is a genetically modified cell comprising, introduced thereinto, a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain and an intracellular signaling domain.Type: ApplicationFiled: September 15, 2017Publication date: July 4, 2019Applicants: KISSEI PHARMACEUTICAL CO., LTD., SHINSHU UNIVERSITYInventors: Yozo Nakazawa, Kazuyuki Matsuda, Shigeru Nakano
-
Publication number: 20190202924Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: ApplicationFiled: March 19, 2019Publication date: July 4, 2019Applicant: CANTARGIA ABInventors: Helena GERSTAMÅ, Thoas FIORETOS, Marcus JÄRÁS, Cecilia Ann-Christin MALMBORG HAGER, Kjell SJÖSTRÖM, Agneta SVEDBERG, Karin VON WACHENFELDT
-
Publication number: 20190202925Abstract: The composition of anti-TNFR2 antibodies are provided, as well as methods of their preparation and use. This includes methods for treating disorders associated with TNF and/or TNFR2, such as cancer.Type: ApplicationFiled: November 10, 2016Publication date: July 4, 2019Applicant: OPI VI - HoldCo LLCInventor: Peter Armstrong THOMPSON
-
Publication number: 20190202926Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: ApplicationFiled: December 1, 2016Publication date: July 4, 2019Inventors: Frank BEURSKENS, Marije OVERDIJK, Rob DE JONG, David SATIJN, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20190202927Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: November 13, 2018Publication date: July 4, 2019Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
-
Publication number: 20190202928Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: March 13, 2019Publication date: July 4, 2019Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
-
Publication number: 20190202929Abstract: The present invention is based, in part, on the identification of novel USP10 biomarkers and modulators, and methods of use thereof, for identifying, assessing, preventing, and treating AML.Type: ApplicationFiled: September 20, 2017Publication date: July 4, 2019Inventors: Sara Buhrlage, Ellen Weisberg, James D. Griffin
-
Publication number: 20190202930Abstract: Provided herein are methods of identifying a subpopulation of ovarian cancer patients who would be responsive to treatment regimens that target folate receptor alpha (FRA)-expressing ovarian tumors and methods of treatment of such patients using an anti-FRA therapeutic agent, such as an antigen-binding protein (e.g., antibody or antigen-binding fragment thereof) that specifically binds to FRA. Also provided are related kits for identification and treatment of the subpopulation of ovarian cancer patients.Type: ApplicationFiled: March 19, 2019Publication date: July 4, 2019Inventors: Charles SCHWEIZER, Daniel John O'SHANNESSY
-
Publication number: 20190202931Abstract: The disclosure relates to fusion proteins, methods of making fusion proteins, and methods of using fusion proteins, wherein the fusion proteins comprise a functional single-domain antibody (sdAb) or a functional variant thereof and a cytosine deaminase (CD) protein or a functional variant thereof, optionally connected via a peptide linker. The fusion proteins of the disclosure also have CD activity. The disclosure also relates to pharmaceutical compositions or formulations comprising such fusion proteins and pharmaceutically acceptable excipients, as well as medical uses of these fusion proteins.Type: ApplicationFiled: January 4, 2019Publication date: July 4, 2019Applicants: LUMOSA THERAPEUTICS, CO., LTD., SHANGHAI LUMOSA THERAPEUTICS, CO., LTD.Inventors: Pei-Jiun CHEN, Shu-Hua LEE
-
Publication number: 20190202932Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.Type: ApplicationFiled: March 13, 2019Publication date: July 4, 2019Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
-
Publication number: 20190202933Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: ApplicationFiled: March 14, 2019Publication date: July 4, 2019Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Publication number: 20190202934Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.Type: ApplicationFiled: March 21, 2019Publication date: July 4, 2019Inventors: Jan TAVERNIER, Sarah GERLO, Frank PEELMAN, Gilles UZE
-
Publication number: 20190202935Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.Type: ApplicationFiled: July 20, 2017Publication date: July 4, 2019Inventors: Chuan-Chu CHOU, Yafeng ZHANG, Shu WU, Zhenyu LIU, Zhongdao LI, Fangliang ZHANG
-
Publication number: 20190202936Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.Type: ApplicationFiled: September 14, 2018Publication date: July 4, 2019Applicant: Genentech, Inc.Inventors: Mark DENNIS, Ryan Jefferson WATTS, Yunhua Yu ZUCHERO, Yin ZHANG
-
Publication number: 20190202937Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.Type: ApplicationFiled: January 8, 2019Publication date: July 4, 2019Inventors: David Paul Humphreys, Shirley Jane Peters
-
Publication number: 20190202938Abstract: The present invention is directed to novel heterodimeric antibodies.Type: ApplicationFiled: March 14, 2019Publication date: July 4, 2019Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Publication number: 20190202939Abstract: A bioelectronic device for regulating stem cell differentiation, a method for differentiating stem cells using the same, and a method for manufacturing the bioelectronic device. According to the present invention, it is possible to effectively control the differentiation of stem cells at a single-cell level, and to simultaneously perform a free radical inhibition function.Type: ApplicationFiled: March 29, 2016Publication date: July 4, 2019Applicant: SOGANG UNIVERSITY RESEARCH FOUNDATIONInventors: Jeong Woo CHOI, Sang Uk KIM, Jin Ho YOON, Mohsen MOHAMMADNIAEI
-
Publication number: 20190202940Abstract: There is described a novel method for processing plant material to produce a cellulose-containing material. The process comprises the steps of: (i) contacting particles of plant material with a peroxide agent and water; (ii) allowing the mixture from step (i) to hydrate until the pH of the mixture is pH 4.5 or less; and (iii) homogenising the mixture from step (ii) and isolating the cellulose-containing-material, and wherein the particles of plant material in step (i) have an average particle diameter of from 10 ?m to 800 ?m.Type: ApplicationFiled: June 23, 2017Publication date: July 4, 2019Inventors: David HEPWORTH, Eric WHALE
-
Publication number: 20190202941Abstract: Products and processes that are related to phosphonated polysaccharide compositions, including phosphonated polysaccharide gels, having a substituent degree of substitution with a lower limit of 0.02 and an upper limit of 3, and having a weight average molecular weight with an upper limit of 5,000,000 g/mole, as well as to oil field application or fracturing fluid compositions comprising such phosphonated polysaccharide compositions.Type: ApplicationFiled: March 6, 2019Publication date: July 4, 2019Applicant: RHODIA OPERATIONSInventors: Laurianne TIMBART, Gilda LIZARRAGA, Gary WOODWARD, Subramanian KESAVAN, David James WILSON
-
Publication number: 20190202942Abstract: The disclosure relates to compositions comprising a polysaccharide derivative. The polysaccharide derivative is a polysaccharide polymer wherein the polymer is substituted with at least one polyether group and/or polyamine group. Compositions comprising the polysaccharide derivative are useful as detergent compositions.Type: ApplicationFiled: June 12, 2017Publication date: July 4, 2019Inventors: Helen S M Lu, Robert Dicosimo, Rong Guan, Weiming Qui
-
Publication number: 20190202943Abstract: A method for producing a hydrogenated conjugated diene polymer latex includes: a hydrogenation step of dissolving or dispersing a hydrogenation catalyst containing a platinum group element in a latex of a conjugated diene polymer to hydrogenate a carbon-carbon unsaturated bond in the conjugated diene polymer; and an insoluble complex formation step of complexing the platinum group element in the latex with a complexing agent to form an insoluble complex, wherein pH of the latex at the insoluble complex formation step is controlled in a range of 5.0 to 8.0.Type: ApplicationFiled: December 13, 2018Publication date: July 4, 2019Applicant: ZEON CORPORATIONInventor: Fuminari OYAMA
-
Publication number: 20190202944Abstract: The present invention is directed at a bulkpolymerisation process for the preparation of a polymer (P) comprising the steps of: (i) providing at least one diene monomer (DM) and optionally at least one comonomer (COM); (ii) contacting the at least one diene monomer (DM) and optionally the at least one comonomer (COM) with a catalyst system (CS) forming a reaction mixture (RM); (iii) polymerizing the reaction mixture (RM) comprising the at least one diene monomer (DM) and optionally the at least one comonomer (COM) in at least one reactor vessel (RV); (iv) isolating the polymer (P) obtained from the at least one reactor vessel (RV); wherein the reaction mixture (RM) comprises solvent, diluent and/or dispersant in an amount of ?10 wt.-%, based on the weight of the reaction mixture (RM); and wherein the conversion rate of the diene monomer (DM) and optionally the comonomer (COM) is ?80%.Type: ApplicationFiled: June 29, 2017Publication date: July 4, 2019Inventors: Marcus Vater, Ulrich Wendler, Michael Bartke
-
Publication number: 20190202945Abstract: A hermetically-sealed, flexible polymer gel cylinder comprising: a flexible polymer gel cylinder having a diameter, Ddry, and comprising a solvent that enhances the plasticity of the polymer gel cylinder compared an otherwise identical polymer gel cylinder with essentially no solvent, wherein the solvent is at an amount such that the flexible polymer gel, after being removed from the package and saturated with the solvent, has a swelled diameter, Dswell, and wherein Ddry?Dswell?5Ddry; and a package hermitically sealing the flexible polymer gel cylinder.Type: ApplicationFiled: January 2, 2019Publication date: July 4, 2019Inventor: Leandro Gil-Silva
-
Publication number: 20190202946Abstract: To provide a photosensitive composition for hologram recording that enables further improvement in diffraction characteristic.—A photosensitive composition for hologram recording that includes at least two kinds of photopolymerizable monomers, a photopolymerization initiator, a binder resin, and a polymerization inhibitor. The at least two kinds of photopolymerizable monomers are a monofunctional monomer and a polyfunctional monomer.Type: ApplicationFiled: August 30, 2017Publication date: July 4, 2019Applicant: SONY CORPORATIONInventors: Hisaya HARA, Eri IGARASHI, Kenshiro KAWASAKI
-
Publication number: 20190202947Abstract: The disclosure relates to compositions containing 1,1-disubstituted alkene compounds capable of preparing polymers having glass transition temperatures above room temperature. The present teaching also relates to polymers prepared 1,1-disubstituted alkene compounds which exhibit glass transition temperatures of 60° C. The disclosure also relate to methods for enhancing the glass transition temperatures of polymers prepared from 1,1-disubstituted alkene compounds.Type: ApplicationFiled: December 29, 2017Publication date: July 4, 2019Inventors: Jeffrey M. Sullivan, Aniruddha Palsule, Alexander R. Holzer, Kshitij K. Parab, Ami Doshi
-
Publication number: 20190202948Abstract: The present invention relates to: a polymerizable compound represented by a formula (I), wherein each of Y1 to Y8 independently represents —O—, —O—C(?O)—, —C(?O)—O— or the like; each of A2, A3, G1, and G2 independently represents a divalent linear aliphatic group having 1 to 20 carbon atoms or the like; each of Z1 and Z2 independently represents an alkenyl group having 2 to 10 carbon atoms or the like; Ax represents an organic group having 2 to 30 carbon atoms that includes at least one aromatic ring; Ay represents a hydrogen atom, an alkyl group having 1 to 20 carbon atoms or the like; A1 represents a trivalent aromatic group or the like; each of A4 and A5 independently represents a divalent aromatic group having 6 to 30 carbon atoms or the like; and Q1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or the like; and others.Type: ApplicationFiled: March 11, 2019Publication date: July 4, 2019Applicant: ZEON CORPORATIONInventor: Kei SAKAMOTO
-
Publication number: 20190202949Abstract: The present invention relates to a new transition metal compound based on cyclopenta[b]fluorenyl group, a transition metal catalyst composition containing the same and having high catalytic activity for preparing an ethylene homopolymer or a copolymer of ethylene and one ?-olefin, a method of preparing an ethylene homopolymer or a copolymer of ethylene and ?-olefin using the same, and the prepared ethylene homopolymer or the copolymer of ethylene and ?-olefin.Type: ApplicationFiled: March 5, 2019Publication date: July 4, 2019Inventors: Dong Cheol Shin, Jong Sok Hahn, Chan Woong Jeon, Jeong Hwan Kim, Seong Kyun Kim, Sun Young Kim, Ho Seong Lee, Sang Ick Lee
-
Publication number: 20190202950Abstract: Catalyst compositions and polymerization systems include at least one thiourea complex according to Formula (I): MQaX4-a (I) in which M is Ti, Zr, or Hf; a is 1 or 2; each group Q of the thiourea complex is a bidentate thiourea ligand bound to the metal center and having Formula (Ia), Formula (Ib), or Formula (Ic): (Formulas should be inserted here). In Formulas (Ia), (Ib), and (Ic), each group R1, R2, and R3 is independently chosen from alkyl groups or aryl groups; each group Z1 or Z2 is independently chosen from alkylene groups. If a=2, groups R1 of the two groups Q are optionally linked, or groups R3 of the two groups Q are optionally linked. Each X is covalently bonded or coordinated to the metal center and is independently chosen from alkyl groups or halides. The polymerization systems may be configured to copolymerize ethylene and ?-olefins.Type: ApplicationFiled: September 13, 2017Publication date: July 4, 2019Applicant: Dow Global Technologies LLCInventors: Arkady L. Krasovskiy, Endre Szuromi
-
Publication number: 20190202951Abstract: A copolymer having tetrafluoroethylene units and second polymerized monomer units in a range from 0.2 to 1 percent by weight, based on the total weight of the copolymer. Rf is a linear or branched perfluoroalkyl group having from 1 to 8 carbon atoms and optionally interrupted by one or more —O— groups, n is independently from 1 to 6, and z is 0, 1, or 2. The copolymer has a melt flow index in a range from 0.02 grams per 10 minutes to 19.4 grams per 10 minutes. The copolymer can be extruded to make articles, such as insulated cables. A method of making the copolymer is also disclosed.Type: ApplicationFiled: August 1, 2017Publication date: July 4, 2019Inventors: Harald Kaspar, Klaus Hintzer, Markus E. Hirschberg, Herbert Koenigsmann, Karl D. Weilandt, Tilman C. Zipplies
-
Publication number: 20190202952Abstract: A molding material comprising a pellet group of at least 20 saponified ethylene-vinyl ester-based copolymer pellets, wherein at least 95% of the pellets have a surface that is substantially a single closed surface, and when a maximum outer diameter of a pellet is taken as a long diameter and a minimum diameter in a cross section having the greatest area among the cross sections perpendicular to the long diameter is taken as a short diameter, the average value of the long diameter/short diameter ratio of at least 20 pellets taken from the pellet group is 1.6 or less and the standard deviation of the long diameter/short diameter ratio of the at least 20 pellets is 0.13 or less.Type: ApplicationFiled: March 6, 2019Publication date: July 4, 2019Applicant: THE NIPPON SYNTHETIC CHEMICAL INDUSTRY CO., LTD.Inventors: Daichi NISHIMURA, Makoto HATANAKA, Shintaro USUI
-
Publication number: 20190202953Abstract: Disclosed herein is a composition comprising a first low molecular weight molecule that is radically polymerizable; a second low molecular weight molecule that is ionically polymerizable; and an initiator package that comprises a free radical initiator, an ionic accelerator and an ionic initiator; where the first low molecular weight molecule undergoes a radical polymerization reaction when subjected to a first form of activation stimuli and where the second low molecular weight molecule undergoes an ionic polymerization reaction in a spatially propagating reaction front or in a global reaction that occurs throughout the entire composition; where the ionic polymerization is initiated by a second form of activation stimuli.Type: ApplicationFiled: August 23, 2017Publication date: July 4, 2019Inventors: Alan James LESSER, Matthew LAMPE
-
Publication number: 20190202954Abstract: A composition of matter includes a mixture of styrene derivative monomers and methacrylate and/or acrylate derivative monomers, which have one or more urethane, carbamate, amide, and/or amine functional groups, and initiators, and the compositions are used to achieve composition control of the forming polymer, with the mole fraction of acrylate/methacrylate and styrene moieties in the forming polymer determined by the chemistry and composition of the feeding monomers.Type: ApplicationFiled: March 6, 2019Publication date: July 4, 2019Applicant: ADA FoundationInventor: Jirun Sun
-
Publication number: 20190202955Abstract: New monomer and polymer materials that comprise one or more Te atoms. In one aspect, tellurium-containing monomers and polymers are provided that are useful for Extreme Ultraviolet Lithography.Type: ApplicationFiled: December 31, 2018Publication date: July 4, 2019Inventors: Emad Aqad, James F. Cameron, James W. Thackeray
-
Publication number: 20190202956Abstract: The present invention relates to a method of preparing grafted copolymers of lignin and/or cellulose, comprising the generation of macroradicals in situ by mechanical impact on the backbone of said lignin and/or cellulose of said lignin and/or cellulose containing material and grafting monomers and/or polymers to said backbone. Furthermore, the present invention relates to the grafted copolymers obtainable by said method, composite materials comprising said copolymers as well as to uses thereof.Type: ApplicationFiled: August 24, 2017Publication date: July 4, 2019Inventor: Eric Yijing Zhang
-
Publication number: 20190202957Abstract: A silane-grafted polyolefin composition is disclosed and includes a desired reduced specific weight material. The composition finds application in a wide array of uses, and in particular automotive and uses such as windshield wipers, where this composition is used in place of conventional materials such as TPV and EPDM rubber formulations.Type: ApplicationFiled: March 9, 2019Publication date: July 4, 2019Applicant: Cooper Standard Automotive, Inc.Inventors: Krishnamachari Gopalan, Robert J. Lenhart, Gending Ji
-
Publication number: 20190202958Abstract: A composite material comprises a polymer matrix having microstructure filler materials that comprise a plurality of interconnected units wherein the units are formed of connected tubes. The tubes may be formed by photo-initiating the polymerization of a monomer in a pattern of interconnected units to form a polymer microlattice, removing unpolymerized monomer, coating the polymer microlattice with a metal, removing the polymer microlattice to leave a metal microlattice, growing or depositing a material on the metal microlattice such as graphene, hexagonal boron nitride or other ceramic, and subsequently removing the metal microlattice.Type: ApplicationFiled: December 21, 2018Publication date: July 4, 2019Inventors: Nazila DADVAND, Benjamin Stassen COOK, Archana VENUGOPAL, Luigi COLOMBO
-
Publication number: 20190202959Abstract: In a conventional self-healing material, although the resin properties after self-healing are restored to the same level as the initial refractoriness and strength of the resin, no further extension of life can be expected. A resin cured product according to the present invention includes: a first vinyl monomer having an ester bond; a second vinyl monomer having a hydroxyl group; a transesterification reaction catalyst; and a boron compound.Type: ApplicationFiled: July 7, 2017Publication date: July 4, 2019Applicant: HITACHI, LTD.Inventors: Yuri KAJIHARA, Takahito MURAKI, Yasuhiko TADA, Jun NUNOSHIGE, Takeshi KONDO
-
Publication number: 20190202960Abstract: The present invention pertains to a fluoropolymer composition comprising an organic colouring compound, to a process for the manufacture of said composition and to uses of said composition in various applications.Type: ApplicationFiled: September 13, 2017Publication date: July 4, 2019Inventors: Martina CORASANITI, Marco DOSSI, Marco AVATANEO, Matteo FANTONI, Satchit SRINIVASAN
